HIF1A and PPARG in cardiac hypertropthy (WP2456)

Homo sapiens

The genes hypoxia-inducible factor 1A and peroxisome proliferator activated receptor gamma play a role in regulating glycolysis, triacylglyceride synthesis, and ultimately hypertrophic cardiomyopathy. This diagram is derived from figure 6D in [https://pubmed.ncbi.nlm.nih.gov/19490906/ PMID 19490906]: "Schematic representation of the coregulation of glycolysis and glycerolipid synthesis by HIF1A. Hypertrophy-induced HIF1A accumulation is predicted to simultaneously promote the transcriptional upregulation of glycolytic enzymes and the direct transcriptional activation of the PPARG promoter. PPARG activity would lead to the upregulation of its target genes, GPD1 and GPAT, leading to promotion of glycerolipid biosynthesis, culminating in TAG accumulation. A secondary level of coordination is predicted to occur via the shuttling of NADH and NAD+ between GAPDH and GPD1. Thus, coordinated regulation of both these components by HIF1A is hypothesized to favor cardiomyocyte lipid accumulation in hypertrophy." This pathway is part the [https://assays.cancer.gov/available_assays?wp_id=WP2456 CPTAC Assay Portal].

Authors

M Aguirre , Jonathan Mélius , Chris Evelo , Kristina Hanspers , Friederike Ehrhart , Alex Pico , Finterly Hu , and Eric Weitz

Activity

last edited

Discuss this pathway

Check for ongoing discussions or start your own.

Cited In

Are you planning to include this pathway in your next publication? See How to Cite and add a link here to your paper once it's online.

Organisms

Homo sapiens

Communities

Annotations

Cell Type Ontology

cardiac muscle cell

Pathway Ontology

glycolysis/gluconeogenesis pathway regulatory pathway lipid metabolic pathway

Disease Ontology

hypertrophic cardiomyopathy

Participants

Label Type Compact URI Comment
Glyceraldehyde-3-phosphate Metabolite kegg.compound:C00118
Pyruvate Metabolite kegg.compound:C00022
Fructose-1,6-biphosphate Metabolite kegg.compound:C05378
Dihydroxyacetonephosphate Metabolite kegg.compound:C00111
Lactate Metabolite kegg.compound:C00186
Glycerol-3-phosphate Metabolite kegg.compound:C00093
Lysophosphatidate Metabolite kegg.compound:C00681
Triacylglycerol Metabolite kegg.compound:C00422
Diacylglycerol Metabolite kegg.compound:C00165
Glucose Metabolite kegg.compound:C00031
Fatty acid Metabolite chebi:35366
NADH Metabolite chebi:16908
NAD+ Metabolite chebi:15846
H+ Metabolite chebi:49637
Pi Metabolite chebi:28659
Acetyl-CoA Metabolite chebi:49637
CoA-SH Metabolite chebi:15346
GAPDH GeneProduct ensembl:ENSG00000111640
LDHA GeneProduct ensembl:ENSG00000134333
TPI1 GeneProduct ensembl:ENSG00000111669
GPD1 GeneProduct ensembl:ENSG00000167588
GPAT3 GeneProduct ensembl:ENSG00000138678
SLC2A1 GeneProduct ensembl:ENSG00000117394
PPARG GeneProduct ensembl:ENSG00000132170
HIF1A GeneProduct ensembl:ENSG00000100644
CD36 GeneProduct ensembl:ENSG00000135218

References

  1. Activation of a HIF1alpha-PPARgamma axis underlies the integration of glycolytic and lipid anabolic pathways in pathologic cardiac hypertrophy. Krishnan J, Suter M, Windak R, Krebs T, Felley A, Montessuit C, et al. Cell Metab. 2009 Jun;9(6):512–24. PubMed Europe PMC Scholia